Clarus Therapeutics Holdings, Inc. (CRXT) |
|
0.2832 -0 (-0.04%)
|
08-19 00:48 |
|
Open: |
0.2833 |
Pre. Close: |
0.2833 |
|
High:
|
0.2979 |
Low:
|
0.262 |
|
Volume:
|
2,200,295 |
Market Cap:
|
15(M) |
|
|
|
|
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.31 - 0.31 |
0.31 - 0.31 |
|
Low:
|
0.28 - 0.28 |
0.28 - 0.28 |
|
Close:
|
0.28 - 0.28 |
0.28 - 0.29 |
|
Technical analysis |
as of: 2022-08-18 3:51:48 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.39 One year: 0.45 |
| Support: |
Support1: 0.26 Support2: 0.21 |
| Resistance: |
Resistance1: 0.34 Resistance2: 0.38 |
| Pivot: |
0.3  |
| Moving Average: |
MA(5): 0.3  MA(20): 0.3
MA(100): 0.57 MA(250): 2.39 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 26.7 %D(3): 50.1 |
| RSI: |
RSI(14): 38.8 |
| 52-week: |
High: 31.23 Low: 0.26 |
| Average Vol(K): |
3-Month: 2,836 (K) 10-Days: 1,418 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CRXT ] has closed above bottom band by 26.1%. Bollinger Bands are 87.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 69 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Thu, 18 Aug 2022
Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction - Yahoo Finance
Thu, 11 Aug 2022
Clarus Therapeutics (NASDAQ:CRXT) and Gamida Cell (NASDAQ:GMDA) Head to Head Survey - Defense World
Sat, 06 Aug 2022
Financial Review: Aziyo Biologics (NASDAQ:AZYO) and Clarus Therapeutics (NASDAQ:CRXT) - Defense World
Thu, 28 Jul 2022
Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate) - Yahoo Finance
Wed, 25 May 2022
Is Clarus Therapeutics Holdings Inc (CRXT) a Good Choice in Drug Manufacturers - General Wednesday? - InvestorsObserver
Mon, 16 May 2022
Clarus Therapeutics Holdings, Inc. (CRXT) CEO Bob Dudley on Q1 2022 Results - Earnings Call Transcript - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—General |
| Shares Out. |
52 (M) |
| Shares Float |
32 (M) |
|
% Held by Insiders
|
2.5 (%) |
|
% Held by Institutions
|
23.3 (%) |
|
Shares Short
|
2,000 (K) |
|
Shares Short P.Month
|
3,310 (K) |
Stock Financials |
|
EPS
|
-2.8 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-1.24 |
|
Profit Margin (%)
|
-256.2 |
|
Operating Margin (%)
|
-271.8 |
|
Return on Assets (ttm)
|
-89.6 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
72 |
|
Gross Profit (p.s.)
|
0.21 |
|
Sales Per Share
|
0.3 |
|
EBITDA (p.s.)
|
-0.82 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-54 (M) |
|
Levered Free Cash Flow
|
-43 (M) |
Stock Valuations |
|
PE Ratio
|
-0.11 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-0.23 |
|
Price to Sales
|
0.93 |
|
Price to Cash Flow
|
-0.28 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
